Boston Immune Technologies & Therapeutics
Clay Thorp is a seasoned professional in the venture capital and pharmaceutical industries, currently serving as General Partner at Hatteras Venture Partners. Previous roles include Chairman of PhaseBio Pharmaceuticals, General Partner at both BioVista Capital (now Hatteras BioCapital) and Catalysta Partners, and Director of Corporate Development at Novalon Pharmaceutical Corporation. Clay's career began with a co-director position at the Student Coalition for Action in Literacy Education (SCALE). Educational qualifications include a master's degree in Public Policy with a concentration in Business/Government from the Harvard Kennedy School and a BA in Math and Art History from the University of North Carolina at Chapel Hill.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Boston Immune Technologies & Therapeutics
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.